Pelvic organ-preserving radical cystectomy versus standard radical cystectomy in female patients diagnosed with bladder cancer.
Bladder cancer
Pelvic organ-preserving radical cystectomy
Radical cystectomy
SEER database
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
09
03
2024
accepted:
13
08
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
24
8
2024
Statut:
epublish
Résumé
Pelvic organ-preserving radical cystectomy (POPRC) has been reported to result in a better postoperative quality of life in female with bladder cancer compared to standard radical cystectomy (SRC). However, its oncological outcomes remain a concern. Female patients with bladder cancer who underwent POPRC or SRC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was used to identify predictors of POPRC usage. To avoid the potential impact of baseline differences between groups on survival, a 1:2 propensity score matching (PSM) was implemented. After that, Kaplan-Meier curves and Log-rank tests were used to determine the significance of overall survival (OS) differences between patients in the SRC group and POPRC group. Finally, subgroup analysis based on predetermined indicators was performed. A total of 2193 patients were included with a median follow-up of 53 months, of whom 233 (10.6%) received POPRC and 1960 (89.4%) received SRC. No definitive predictors of POPRC were identified. Before PSM, POPRC resulted in comparable OS to SRC (HR = 1.09, p = 0.309), while after PSM, POPRC was associated with significantly worse OS (HR = 1.23, p = 0.038). In subgroup analyses, POPRC led to non-inferior OS (HR = 1.18, 95%CI 0.71-1.95, p = 0.531) in patients with non-muscle invasive bladder cancer (NMIBC) and T2 patients (HR = 1.07, p = 0.669), but significantly worse OS in T3 patients (HR = 1.41, p = 0.02). Currently, patients undergoing POPRC have not undergone strict screening, and candidates for POPRC should have more stringent criteria in the future to achieve satisfactory oncological outcomes. However, flaws in the study make more evidence needed to support our findings.
Sections du résumé
BACKGROUND
BACKGROUND
Pelvic organ-preserving radical cystectomy (POPRC) has been reported to result in a better postoperative quality of life in female with bladder cancer compared to standard radical cystectomy (SRC). However, its oncological outcomes remain a concern.
PATIENTS AND METHODS
METHODS
Female patients with bladder cancer who underwent POPRC or SRC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was used to identify predictors of POPRC usage. To avoid the potential impact of baseline differences between groups on survival, a 1:2 propensity score matching (PSM) was implemented. After that, Kaplan-Meier curves and Log-rank tests were used to determine the significance of overall survival (OS) differences between patients in the SRC group and POPRC group. Finally, subgroup analysis based on predetermined indicators was performed.
RESULTS
RESULTS
A total of 2193 patients were included with a median follow-up of 53 months, of whom 233 (10.6%) received POPRC and 1960 (89.4%) received SRC. No definitive predictors of POPRC were identified. Before PSM, POPRC resulted in comparable OS to SRC (HR = 1.09, p = 0.309), while after PSM, POPRC was associated with significantly worse OS (HR = 1.23, p = 0.038). In subgroup analyses, POPRC led to non-inferior OS (HR = 1.18, 95%CI 0.71-1.95, p = 0.531) in patients with non-muscle invasive bladder cancer (NMIBC) and T2 patients (HR = 1.07, p = 0.669), but significantly worse OS in T3 patients (HR = 1.41, p = 0.02).
CONCLUSION
CONCLUSIONS
Currently, patients undergoing POPRC have not undergone strict screening, and candidates for POPRC should have more stringent criteria in the future to achieve satisfactory oncological outcomes. However, flaws in the study make more evidence needed to support our findings.
Identifiants
pubmed: 39182105
doi: 10.1186/s12957-024-03502-6
pii: 10.1186/s12957-024-03502-6
doi:
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
218Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 .
doi: 10.3322/caac.21660
pubmed: 33538338
Cumberbatch M, Jubber I, Black PC, et al. Epidemiology of bladder Cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–95. https://doi.org/10.1016/j.eururo.2018.09.001 .
doi: 10.1016/j.eururo.2018.09.001
pubmed: 30268659
Alfred Witjes J, Max Bruins H, Carrión A, et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder Cancer: Summary of the 2023 guidelines. Eur Urol. 2024;85(1):17–31. https://doi.org/10.1016/j.eururo.2023.08.016 .
doi: 10.1016/j.eururo.2023.08.016
pubmed: 37858453
Flaig TW, Spiess PE, Agarwal N, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(3):329–54. https://doi.org/10.6004/jnccn.2020.0011 .
doi: 10.6004/jnccn.2020.0011
pubmed: 32135513
Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017;198(3):552–9. https://doi.org/10.1016/j.juro.2017.04.086 .
doi: 10.1016/j.juro.2017.04.086
pubmed: 28456635
pmcid: 5626446
Stenzl A, Nagele U, Kuczyk M, Sievert KD, Anastasiadis A, Seibold J, et al. Cystectomy – Technical considerations in male and female patients. EAU Update Ser. 2005;3:138.
doi: 10.1016/j.euus.2005.07.004
von Deimling M, Laukhtina E, Pradere B, et al. Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review. Transl Androl Urol. 2022;11(11):1598–610. https://doi.org/10.21037/tau-22-463 .
doi: 10.21037/tau-22-463
Veskimäe E, Neuzillet Y, Rouanne M, et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int. 2017;120(1):12–24. https://doi.org/10.1111/bju.13819 .
doi: 10.1111/bju.13819
pubmed: 28220653
Large M, Prasad S, Patel A, Jayram G, Ganshert C, Steinberg G. Can vaginal-sparing cystectomy be safely attempted in all women undergoing radical cystectomy? A single institution study of perioperative and oncological outcomes. J Urol. 2012;187(Suppl):e473–4.
Zhong W, Xia K, Liu L, et al. Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis. Int J Surg. 2023;109(9):2742–50. https://doi.org/10.1097/JS9.0000000000000516 .
doi: 10.1097/JS9.0000000000000516
pubmed: 37335987
pmcid: 10498867
Ali-El-Dein B, Mosbah A, Osman Y, et al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up. Eur J Surg Oncol. 2013;39(4):358–64. https://doi.org/10.1016/j.ejso.2013.02.004 .
doi: 10.1016/j.ejso.2013.02.004
pubmed: 23422323
Kulkarni JN, Rizvi SJ, Acharya UP, et al. Gynecologic-tract sparing extra peritoneal retrograde radical cystectomy with neobladder. Int Braz J Urol. 2008;34(2):180–7. https://doi.org/10.1590/s1677-55382008000200008 . discussion 187 – 90.
doi: 10.1590/s1677-55382008000200008
pubmed: 18462516
Wishahi M, Elganozoury H. Survival up to 5–15 years in young women following genital sparing radical cystectomy and neobladder: oncological outcome and quality of life. Single-surgeon and single-institution experience. Cent Eur J Urol. 2015;68(2):141–5. https://doi.org/10.5173/ceju.2015.475 .
doi: 10.5173/ceju.2015.475
Moursy EE, Eldahshoursy MZ, Gamal WM, et al. Orthotopic genital sparing radical cystectomy in pre-menopausal women with muscle-invasive bladder carcinoma: a prospective study. Indian J Urol. 2016;32(1):65–70. https://doi.org/10.4103/0970-1591.173112 .
doi: 10.4103/0970-1591.173112
pubmed: 26941498
pmcid: 4756555
Surveillance E, Results E. (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 17 Registries, Nov 2022 Sub (2000–2020) - Linked To County Attributes - Time Dependent (1990–2021) Income/Rurality, 1969–2021 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2023, based on the November 2022 submission.
Rammant E, Van Wilder L, Van Hemelrijck M, et al. Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review. Qual Life Res. 2020;29(11):2887–910. https://doi.org/10.1007/s11136-020-02544-z .
doi: 10.1007/s11136-020-02544-z
pubmed: 32504291
Zahran MH, Fahmy O, El-Hefnawy AS, et al. Female sexual dysfunction post radical cystectomy and urinary diversion. Climacteric. 2016;19(6):546–50. https://doi.org/10.1080/13697137.2016.1225714 .
doi: 10.1080/13697137.2016.1225714
pubmed: 27649461
Badawy AA, Abolyosr A, Mohamed ER, et al. Orthotopic diversion after cystectomy in women: a single-centre experience with a 10-year follow-up. Arab J Urol. 2011;9(4):267–71. https://doi.org/10.1016/j.aju.2011.10.007 .
doi: 10.1016/j.aju.2011.10.007
pubmed: 26579310
pmcid: 4150594
Bhatt A, Nandipati K, Dhar N, et al. Neurovascular preservation in orthotopic cystectomy: impact on female sexual function. Urology. 2006;67(4):742–5. https://doi.org/10.1016/j.urology.2005.10.015 .
doi: 10.1016/j.urology.2005.10.015
pubmed: 16566975
Hautmann RE, Abol-Enein H, Davidsson T, et al. ICUD-EAU International Consultation on bladder Cancer 2012: urinary diversion. Eur Urol. 2013;63(1):67–80. https://doi.org/10.1016/j.eururo.2012.08.050 .
doi: 10.1016/j.eururo.2012.08.050
pubmed: 22995974
Lavallée E, Dovey Z, Pathak P, et al. Functional and oncological outcomes of female pelvic organ-preserving Robot-assisted Radical Cystectomy. Eur Urol Open Sci. 2022;36:34–40. https://doi.org/10.1016/j.euros.2021.11.010 .
doi: 10.1016/j.euros.2021.11.010
pubmed: 35005650
Booth BB, Rasmussen A, Jensen JB. Evaluating sexual function in women after radical cystectomy as treatment for bladder cancer. Scand J Urol. 2015;49(6):463–7. https://doi.org/10.3109/21681805.2015.1055589 .
doi: 10.3109/21681805.2015.1055589
pubmed: 26087867
Parker WH. Bilateral oophorectomy versus ovarian conservation: effects on long-term women’s health. J Minim Invasive Gynecol. 2010;17(2):161–6. https://doi.org/10.1016/j.jmig.2009.12.016 .
doi: 10.1016/j.jmig.2009.12.016
pubmed: 20226402
Whittum M, Hussein AA, Ahmed YE, et al. Gynecological organ involvement at robot-assisted radical cystectomy in females: is anterior exenteration necessary. Can Urol Assoc J. 2018;12(9):E398–398402. https://doi.org/10.5489/cuaj.5086 .
doi: 10.5489/cuaj.5086
pubmed: 29787373
pmcid: 6143501
Bai S, Yao Z, Zhu X, et al. The feasibility and safety of Reproductive Organ preserving Radical Cystectomy for Elderly female patients with muscle-invasive bladder Cancer: a retrospective propensity score-matched study. Urology. 2019;125:138–45. https://doi.org/10.1016/j.urology.2018.09.035 .
doi: 10.1016/j.urology.2018.09.035
pubmed: 30445122
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, et al. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39:4363–71.
doi: 10.1007/s00345-021-03776-5
pubmed: 34196758
Marcq G, Afferi L, Neuzillet Y, Nykopp T, Voskuilen CS, Furrer MA, et al. Oncological outcomes for patients harboring positive Surgical margins following radical cystectomy for muscle-invasive bladder Cancer: a Retrospective Multicentric Study on Behalf of the YAU Urothelial Group. Cancers (Basel). 2022;14:5740.
doi: 10.3390/cancers14235740
pubmed: 36497222
Gregg JR, Emeruwa C, Wong J, et al. Oncologic outcomes after Anterior Exenteration for muscle invasive bladder Cancer in women. J Urol. 2016;196(4):1030–5. https://doi.org/10.1016/j.juro.2016.04.090 .
doi: 10.1016/j.juro.2016.04.090
pubmed: 27164514
Taylor BL, Matrai CE, Smith AL, et al. Gynecologic organ involvement during radical cystectomy for bladder Cancer: is it time to routinely spare the ovaries. Clin Genitourin Cancer. 2019;17(1):e209–209215. https://doi.org/10.1016/j.clgc.2018.10.009 .
doi: 10.1016/j.clgc.2018.10.009
pubmed: 30470630
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023;132:170–80.
doi: 10.1111/bju.15984
pubmed: 36748180
Stroman L, Nair R, Russell B, Malik N, Desai A, Chandra A, et al. The impact of non-urothelial variant histology on oncological outcomes following radical cystectomy. BJU Int. 2019;124:418–23.
doi: 10.1111/bju.14704
pubmed: 30740862
D’Andrea D, Shariat SF, Soria F, Mari A, Mertens LS, Di Trapani E, et al. The impact of primary Versus secondary muscle-invasive bladder Cancer at diagnosis on the response to Neoadjuvant Chemotherapy. Eur Urol Open Sci. 2022;41:74–80.
doi: 10.1016/j.euros.2022.05.001
pubmed: 35813257
pmcid: 9257642
Vlaming M, Kiemeney L, van der Heijden AG. Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer. Cancer Treat Res Commun. 2020;25:100264.
doi: 10.1016/j.ctarc.2020.100264
pubmed: 33316558
Claps F, Pavan N, Ongaro L, Tierno D, Grassi G, Trombetta C, et al. BCG-Unresponsive non-muscle-invasive bladder Cancer: Current Treatment Landscape and Novel emerging molecular targets. Int J Mol Sci. 2023;24:12596.
doi: 10.3390/ijms241612596
pubmed: 37628785
pmcid: 10454200